Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GSK Files NDA for LAMA/LABA Combination Drug for COPD Treatment
April 24, 2013
- Shionogi Revises Profit Forecasts for FY2012
April 24, 2013
- AnGes MG’s CIN Therapeutic Vaccine Demonstrates Increased Efficacy in Combination with Kampo Medicine
April 24, 2013
- Merck Serono to Launch New Gonalef Pen Devices Starting in May
April 24, 2013
- Ibandronate Injection Non-Inferior to Risedronate: Chugai, Taisho
April 23, 2013
- Nichi-Iko to Launch Allegra AG in June, Says Identical with Original
April 23, 2013
- Daiichi Sankyo Launches Silodosin in China
April 23, 2013
- Ono Pharmaceutical Obtains Exclusive Rights for Once-Daily Wearing-Off Treatment
April 22, 2013
- Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
- Taisho Files SGLT-2 Inhibitor Luseogliflozin, Submits RMP
April 22, 2013
- Merck Serono Obtains Marketing Rights for Cetrotide from Shionogi
April 22, 2013
- AnGes MG, Shionogi to Start PI Study for Nucleic Acid Drug for Atopic Dermatitis
April 19, 2013
- Daiichi Sankyo to Enter Branded Generics Business in Brazil with Launch of 2 Products
April 19, 2013
- Eli Lilly Japan Aims to Be a Top-10 Drug Maker in Japan by 2020, but Re-pricing and Generic Competition Could Pose Obstacles
April 19, 2013
- Tug-of-War over “Conflicts of Interest” (2): “Diovan Scandal” Brings Renewed Attention to COI
April 19, 2013
- Taisho, Nissui Launch Switch OTC Epadel; Prior Doctor Consultation Required for Patients
April 18, 2013
- Meiji Seika Pharma Licenses Schizophrenia Treatment from MSD, to Market It Independently
April 18, 2013
- Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus
April 18, 2013
- Pfizer’s Palbociclib Receives Breakthrough Therapy Designation from US FDA
April 18, 2013
- Teijin, Kyorin Expected to Grow thru “Win-Win” Relationship: Teijin Pharma Pres.
April 17, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…